{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:39:28Z","timestamp":1793403568254,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["No. 252300420543"],"award-info":[{"award-number":["No. 252300420543"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Construction Project of Henan Provincial Medical Science and Technology Research Program","award":["No. LHGJ20240195"],"award-info":[{"award-number":["No. LHGJ20240195"]}]},{"DOI":"10.13039\/501100013057","name":"Innovation Scientists and Technicians Troop Construction Projects of Henan Province","doi-asserted-by":"publisher","award":["No. 254000510006"],"award-info":[{"award-number":["No. 254000510006"]}],"id":[{"id":"10.13039\/501100013057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University","award":["No. ZYCXTD2023008 and QNCXTD2023001"],"award-info":[{"award-number":["No. ZYCXTD2023008 and QNCXTD2023001"]}]},{"name":"Henan Provincial Medical Science and Technology Research Program Provincial and Ministerial Joint Construction Project","award":["No. SBGJ202101012"],"award-info":[{"award-number":["No. SBGJ202101012"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82222007, 82170281, U2004203"],"award-info":[{"award-number":["No. 82222007, 82170281, U2004203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Henan Province Key R&D Program","award":["No. 241111313300"],"award-info":[{"award-number":["No. 241111313300"]}]},{"name":"Henan Province Science and Technology Research Joint Project","award":["No. 222301420054"],"award-info":[{"award-number":["No. 222301420054"]}]},{"name":"Henan Provincial Clinical Medical Scientist Training Project","award":["No. HNCMS202418"],"award-info":[{"award-number":["No. HNCMS202418"]}]},{"name":"Henan Zhongyuan Medical Science and Technology Innovation and Development Foundation Project","award":["No. ZYYC202305ZD"],"award-info":[{"award-number":["No. ZYYC202305ZD"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02800-6","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:49:35Z","timestamp":1765536575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between lipoprotein(a) levels, cumulative lipoprotein(a) burden, and cardiovascular outcomes in patients with acute myocardial infarction: a large-scale cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhenwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"1","key":"2800_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02925-4","volume":"21","author":"J Sun","year":"2023","unstructured":"Sun J, Qiao Y, Zhao M, Magnussen CG, Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15\u201339 years in 204 countries\/territories, 1990\u20132019: a systematic analysis of global burden of disease study 2019. BMC Med. 2023;21(1):222. https:\/\/doi.org\/10.1186\/s12916-023-02925-4.","journal-title":"BMC Med"},{"issue":"11","key":"2800_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","volume":"32","author":"B Chong","year":"2025","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2025;32(11):1001\u201315. https:\/\/doi.org\/10.1093\/eurjpc\/zwae281.","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"2800_CR3","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"issue":"1","key":"2800_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"1","key":"2800_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","volume":"67","author":"RC Hoogeveen","year":"2021","unstructured":"Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem. 2021;67(1):143\u201353. https:\/\/doi.org\/10.1093\/clinchem\/hvaa252.","journal-title":"Clin Chem"},{"key":"2800_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","volume":"59","author":"K Berg","year":"1963","unstructured":"Berg K. A new serum type, system in man\u2013the LP system. Acta Pathol Microbiol Scand. 1963;59:369\u201382. https:\/\/doi.org\/10.1111\/j.1699-0463.1963.tb01808.x.","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"8","key":"2800_CR7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339\u201359. https:\/\/doi.org\/10.1194\/jlr.R067314.","journal-title":"J Lipid Res"},{"issue":"10459","key":"2800_CR8","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet. 2024;404(10459):1255\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(24)01308-4.","journal-title":"Lancet"},{"issue":"6","key":"2800_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","volume":"151","author":"A Greco","year":"2025","unstructured":"Greco A, Finocchiaro S, Spagnolo M, et al. Lipoprotein(a) as a pharmacological target: premises, promises, and prospects. Circulation. 2025;151(6):400\u201315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069210.","journal-title":"Circulation"},{"issue":"23","key":"2800_CR10","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehq386.","journal-title":"Eur Heart J"},{"issue":"1","key":"2800_CR11","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-60. https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2800_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jacl.2020.06.010","volume":"14","author":"EJ Brandt","year":"2020","unstructured":"Brandt EJ, Mani A, Spatz ES, Desai NR, Nasir K. Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. J Clin Lipidol. 2020;14(5):695\u2013e7064. https:\/\/doi.org\/10.1016\/j.jacl.2020.06.010.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2800_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2454975","volume":"57","author":"Z Wang","year":"2025","unstructured":"Wang Z, Tang J, Shi Q, Fang L, Liu N, Zhang J. Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study. Ann Med. 2025;57(1):2454975. https:\/\/doi.org\/10.1080\/07853890.2025.2454975.","journal-title":"Ann Med"},{"issue":"5","key":"2800_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1253\/circj.CJ-18-0970","volume":"83","author":"J Shitara","year":"2019","unstructured":"Shitara J, Kasai T, Konishi H, et al. Impact of lipoprotein (a) levels on long-term outcomes in patients with coronary artery disease and left ventricular systolic dysfunction. Circ J. 2019;83(5):1047\u201353. https:\/\/doi.org\/10.1253\/circj.CJ-18-0970.","journal-title":"Circ J"},{"issue":"1","key":"2800_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19443-4","volume":"24","author":"Z Wang","year":"2024","unstructured":"Wang Z, Yan X, Fang L, Tang J, Zhang J. Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES. BMC Public Health. 2024;24(1):1927. https:\/\/doi.org\/10.1186\/s12889-024-19443-4.","journal-title":"BMC Public Health"},{"issue":"7","key":"2800_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13117","volume":"49","author":"B Gencer","year":"2019","unstructured":"Gencer B, Rigamonti F, Nanchen D, et al. Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. Eur J Clin Invest. 2019;49(7):e13117. https:\/\/doi.org\/10.1111\/eci.13117.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"2800_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.numecd.2019.09.020","volume":"30","author":"N Xu","year":"2020","unstructured":"Xu N, Tang XF, Yao Y, et al. Lipoprotein(a) levels are associated with coronary severity but not with outcomes in Chinese patients underwent percutaneous coronary intervention. Nutr Metab Cardiovasc Dis. 2020;30(2):265\u201373. https:\/\/doi.org\/10.1016\/j.numecd.2019.09.020.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"2800_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106117","volume":"26","author":"P Wang","year":"2023","unstructured":"Wang P, Yuan D, Zhang C, et al. Association between cumulative lipoprotein(a) exposure and adverse cardiovascular outcomes in patients with prediabetes or diabetes. iScience. 2023;26(3):106117. https:\/\/doi.org\/10.1016\/j.isci.2023.106117.","journal-title":"iScience"},{"issue":"Suppl 1","key":"2800_CR19","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2337\/dc13-S067","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):S67\u201374. https:\/\/doi.org\/10.2337\/dc13-S067.","journal-title":"Diabetes Care"},{"issue":"5","key":"2800_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cjca.2020.02.086","volume":"36","author":"DM Rabi","year":"2020","unstructured":"Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada\u2019s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36(5):596\u2013624. https:\/\/doi.org\/10.1016\/j.cjca.2020.02.086.","journal-title":"Can J Cardiol"},{"issue":"5","key":"2800_CR21","first-page":"390","volume":"35","author":"Joint Committee for the Development of Guidelines for the Prevention","year":"2007","unstructured":"Joint Committee for the Development of Guidelines for the Prevention. Treatment of dyslipidemia in Chinese adults. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults. Chin J Cardiovasc Disease. 2007;35(5):390\u2013419.","journal-title":"Chin J Cardiovasc Disease"},{"issue":"10075","key":"2800_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(16)32064-5.","journal-title":"Lancet"},{"issue":"10","key":"2800_CR23","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1681\/ASN.2006040368","volume":"17","author":"YC Ma","year":"2006","unstructured":"Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937\u201344. https:\/\/doi.org\/10.1681\/ASN.2006040368.","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"2800_CR24","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","volume":"163","author":"CB Granger","year":"2003","unstructured":"Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345\u201353. https:\/\/doi.org\/10.1001\/archinte.163.19.2345.","journal-title":"Arch Intern Med"},{"issue":"2","key":"2800_CR25","doi-asserted-by":"publisher","first-page":"e004425","DOI":"10.1136\/bmjopen-2013-004425","volume":"4","author":"KA Fox","year":"2014","unstructured":"Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2):e004425. https:\/\/doi.org\/10.1136\/bmjopen-2013-004425.","journal-title":"BMJ Open"},{"issue":"4","key":"2800_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1194\/jlr.R061648","volume":"57","author":"SM Marcovina","year":"2016","unstructured":"Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526\u201337. https:\/\/doi.org\/10.1194\/jlr.R061648.","journal-title":"J Lipid Res"},{"issue":"3","key":"2800_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/s0002-9149(83)80105-2","volume":"51","author":"GG Gensini","year":"1983","unstructured":"Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606. https:\/\/doi.org\/10.1016\/s0002-9149(83)80105-2.","journal-title":"Am J Cardiol"},{"key":"2800_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2019.05.012","volume":"287","author":"GP Rampidis","year":"2019","unstructured":"Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for Gensini score calculation. Atherosclerosis. 2019;287:181\u20133. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.05.012.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2800_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","volume":"132","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation. 2015;132(4):302\u201361. https:\/\/doi.org\/10.1161\/CIR.0000000000000156.","journal-title":"Circulation"},{"issue":"6","key":"2800_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: Lipoprotein(a). J Am Coll Cardiol. 2017;69(6):692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2800_CR31","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation"},{"issue":"7","key":"2800_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","volume":"79","author":"M Trinder","year":"2022","unstructured":"Trinder M, Paruchuri K, Haidermota S, et al. Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk. J Am Coll Cardiol. 2022;79(7):617\u201328. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.055.","journal-title":"J Am Coll Cardiol"},{"key":"2800_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cca.2020.02.030","volume":"505","author":"JH Contois","year":"2020","unstructured":"Contois JH, Nguyen RA, Albert AL. Lipoprotein(a) particle number assay without error from apolipoprotein(a) size isoforms. Clin Chim Acta. 2020;505:119\u201324. https:\/\/doi.org\/10.1016\/j.cca.2020.02.030.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"2800_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/BF00201550","volume":"86","author":"C Sandholzer","year":"1991","unstructured":"Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607\u201314. https:\/\/doi.org\/10.1007\/BF00201550.","journal-title":"Hum Genet"},{"issue":"11","key":"2800_CR35","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.5551\/jat.38794","volume":"24","author":"S Suwa","year":"2017","unstructured":"Suwa S, Ogita M, Miyauchi K, et al. Impact of lipoprotein (a) on long-term outcomes in patients with coronary artery disease treated with statin after a first percutaneous coronary intervention. J Atheroscler Thromb. 2017;24(11):1125\u201331. https:\/\/doi.org\/10.5551\/jat.38794.","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"2800_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s11239-022-02701-w","volume":"54","author":"A Silverio","year":"2022","unstructured":"Silverio A, Cancro FP, Di Maio M, et al. Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes. J Thromb Thrombolysis. 2022;54(3):382\u201392. https:\/\/doi.org\/10.1007\/s11239-022-02701-w.","journal-title":"J Thromb Thrombolysis"},{"key":"2800_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.atherosclerosis.2022.04.007","volume":"349","author":"Q Li","year":"2022","unstructured":"Li Q, Chen Y, Yu L, et al. The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease. Atherosclerosis. 2022;349:204\u201310. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.007.","journal-title":"Atherosclerosis"},{"key":"2800_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.637366","volume":"8","author":"C Hu","year":"2021","unstructured":"Hu C, Liu J, Han H, et al. A synergistic effect of Lp(a) and GRACE score on cardiovascular risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a cohort study from China. Front Cardiovasc Med. 2021;8:637366. https:\/\/doi.org\/10.3389\/fcvm.2021.637366.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"2800_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5603\/KP.2013.0156","volume":"71","author":"E Guler","year":"2013","unstructured":"Guler E, Gecmen C, Guler GB, et al. Adding lipoprotein(a) levels to the GRACE score to predict prognosis in patients with non-ST elevation acute coronary syndrome. Kardiol Pol. 2013;71(7):695\u2013701. https:\/\/doi.org\/10.5603\/KP.2013.0156.","journal-title":"Kardiol Pol"},{"issue":"12","key":"2800_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101362","volume":"47","author":"N Corpataux","year":"2022","unstructured":"Corpataux N, Hochholzer W, Valina CM, et al. Serum lipoprotein(a) and 3-year outcomes in patients undergoing percutaneous coronary intervention. Curr Probl Cardiol. 2022;47(12):101362. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101362.","journal-title":"Curr Probl Cardiol"},{"issue":"13","key":"2800_CR41","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e102","volume":"38","author":"JS Park","year":"2023","unstructured":"Park JS, Cho KH, Hong YJ, et al. Baseline lipoprotein(a) levels and long-term cardiovascular outcomes after acute myocardial infarction. J Korean Med Sci. 2023;38(13):e102. https:\/\/doi.org\/10.3346\/jkms.2023.38.e102.","journal-title":"J Korean Med Sci"},{"issue":"5","key":"2800_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10654-022-00956-4","volume":"38","author":"M Amiri","year":"2023","unstructured":"Amiri M, Raeisi-Dehkordi H, Verkaar AJCF, et al. Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2023;38(5):485\u201399. https:\/\/doi.org\/10.1007\/s10654-022-00956-4.","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"2800_CR43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/clc.4960270503","volume":"27","author":"A Deb","year":"2004","unstructured":"Deb A, Caplice NM. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004;27(5):258\u201364. https:\/\/doi.org\/10.1002\/clc.4960270503.","journal-title":"Clin Cardiol"},{"issue":"2","key":"2800_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0021-9150(99)00064-7","volume":"143","author":"LB Nielsen","year":"1999","unstructured":"Nielsen LB. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 1999;143(2):229\u201343. https:\/\/doi.org\/10.1016\/s0021-9150(99)00064-7.","journal-title":"Atherosclerosis"},{"issue":"5","key":"2800_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16(5):305\u201318. https:\/\/doi.org\/10.1038\/s41569-018-0153-2.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"2800_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clinbiochem.2003.12.007","volume":"37","author":"MB Boffa","year":"2004","unstructured":"Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37(5):333\u201343. https:\/\/doi.org\/10.1016\/j.clinbiochem.2003.12.007.","journal-title":"Clin Biochem"},{"issue":"17","key":"2800_CR47","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","volume":"73","author":"KH Zheng","year":"2019","unstructured":"Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73(17):2150\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.070.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2800_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","volume":"134","author":"FM van der Valk","year":"2016","unstructured":"van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134(8):611\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.020838.","journal-title":"Circulation"},{"issue":"3","key":"2800_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030461","volume":"10","author":"NC Chang","year":"2021","unstructured":"Chang NC, Yeh CT, Lin YK, et al. Garcinol attenuates lipoprotein(a)-induced oxidative stress and inflammatory cytokine production in ventricular cardiomyocyte through \u03b17-nicotinic acetylcholine receptor-mediated inhibition of the p38 MAPK and NF-\u03baB signaling pathways. Antioxidants. 2021;10(3):461. https:\/\/doi.org\/10.3390\/antiox10030461.","journal-title":"Antioxidants"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02800-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02800-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02800-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:49:36Z","timestamp":1765536576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-025-02800-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02800-6","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Clinical Research Ethics Committee of Zhongda Hospital affiliated to Southeast University (2021ZDSYLL152-P01) and complied with the basic principles of the Declaration of Helsinki, and informed consent was obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}